Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| AstraZeneca prices a €1.4bn bond offering | 30 Jul 2024 |
| Calquence fixed-duration combo improved 1L CLL PFS | 29 Jul 2024 |
| ODAC reviewed Imfinzi in resectable lung cancer | 26 Jul 2024 |
| Half-year Report | 25 Jul 2024 |
| Acquisition of Amolyt Pharma completed | 15 Jul 2024 |
| Lynparza & Imfinzi positive CHMP in endometrial | 1 Jul 2024 |
| Total Voting Rights | 1 Jul 2024 |
| Imfinzi improved EFS and OS in bladder cancer | 25 Jun 2024 |
| Update on Imfinzi ADJUVANT BR.31 trial | 25 Jun 2024 |
| Update on CAPItello-290 Phase III trial | 18 Jun 2024 |
| Imfinzi approved in the US for endometrial cancer | 17 Jun 2024 |
| Director/PDMR Shareholding | 12 Jun 2024 |